title: Androstenedione is the preferred androgen source in hormone refractory prostate cancer--letter.
authors.affiliation: Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. sharifn@ccf.org.
authors.forename: Nima
authors.initials: N
authors.lastname: Sharifi
authors.affiliation: Division of Metabolism, Diabetes, and Endocrinology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Auchus
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D000728:Androgens / Q000378:metabolism*; D000735:Androstenedione / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D000735:Androstenedione